Jennifer R. Brown, MD, PhD

Patterns of duvelisib‐induced lymphocytosis in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma, including those with high‐risk factors, in the DUO trial

Purpose of the Study: Lymphocytosis is a defining feature of chronic lymphocytic leukemia (CLL) and recognized as a class effect of treatment with B‐cell receptor pathway inhibitors....

Shih Chen ;

Samantha Hidy ;

Johnathan Pachter ;

Jennifer R. Brown , MD, PhD;

Matthew S. Davids , MD, MMSc;

David T. Weaver ;

Stephanie Lustgarten ;

Jacqueline Barrientos ;

Ian W. Flinn ;

Amanda Cashen ;

Nicholas Chiorazzi ;

10/23/2019

Update on PI3K Inhibitors: Is Toxicity the Key?

Jennifer R. Brown , MD, PhD;

10/19/2018

Patterns of duvelisib‐induced lymphocytosis in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma, including those with high‐risk factors, in the DUO trial

Purpose of the Study: Lymphocytosis is a defining feature of chronic lymphocytic leukemia (CLL) and recognized as a class effect of treatment with B‐cell receptor pathway inhibitors....

Jacqueline Barrientos ;

Ian W. Flinn ;

Amanda Cashen ;

Nicholas Chiorazzi ;

Shih Chen ;

Samantha Hidy ;

Johnathan Pachter ;

Jennifer R. Brown , MD, PhD;

Matthew S. Davids , MD, MMSc;

David T. Weaver ;

Stephanie Lustgarten ;

10/23/2019

Videos

Analyzing Mechanisms of Pirtobrutinib Resistance Among Patients With CLL Pre-Treated With a Covalent BTK Inhibitor

07/10/2023

Jennifer R. Brown , MD, PhD;

At the 2023 EHA Congress, Jennifer Brown, MD, presented study findings on mechanisms of resistance to pirtobrutinib among patients with chronic lymphocytic leukemia pre-treated with a covalent BTK inhibitor.

At the 2023 EHA Congress,...

07/10/2023

Oncology

Conference Coverage

Extended Follow-up of ALPINE Study Confirms Zanubrutinib Yields Progression-Free Survival Benefit vs Ibrutinib for R/R CLL/SLL

12/11/2023

Jennifer R. Brown , MD, PhD;

At the 65th ASH Annual Meeting, Jennifer R Brown, MD, PhD, presented follow-up data which found that zanubrutinib continued to be a more efficacious treatment than ibrutinib for patients with R/R chronic lymphocytic leukemia/small lymphocytic...

At the 65th ASH Annual Meeting,...

12/11/2023

Oncology

RICHTER’S: WHO WILL GET? WHAT TO DO?

Jennifer R. Brown , MD, PhD;

10/25/2019

Interview

The Road Ahead for CLL Research and Treatment: Overcoming Challenges and Embracing Innovations in Patient Care

10/25/2024

Jennifer R. Brown , MD, PhD;

Learn about recent advancements in CLL treatment including the potential approval of new combination therapies and the evolving landscape of targeted therapies.

Learn about recent advancements...

10/25/2024

Journal of Clinical Pathways